Related Issuers
by Stephen Carter
Jan 28, 2021 10:00 AM ET
Biogroup (BIOGRP) EUR1.05bn (up from EUR1bn) 144A/Reg S 2-part. Via JPM (B&D)/BNP/Natixis joint glocos/Citi/CA/DB/GS/HSBC joint books. List Lux. NY law. Settles 02/09. New term loan size reduced by EUR50m to EUR1.45bn.
- CAB EUR800m (up from EUR750m) sr sec notes due 02/01/28 (7y). NC3 (MWC B+50bp), then at 101.688, 100.844, 100. Equity claw: 3y 40% at 103.375. Special call: 10% per year the 1st 3 years at 103. B2/B-/B+ (negative/stable/stable). Reg S ISIN: XS2294186965. IPT mid to high 3s. Px talk: 3.25%-3.50%. Final terms: EUR800m at 3.375%. Priced:3.375% at 100. +409bp vs DBR 0.5% 02/15/28.
- Laboratoire Eimer EUR250m sr notes due 02/01/29 (8y). NC3 (MWC B+50bp), then at 102.50, 101.25, 100. Equity claw: 3y 40% at 105.00. Caa1/CCC/CCC+ (negative/stable/stable). Reg S ISIN: XS2294187690. IPT mid 5s. Px talk: 5.00%-5.25%. Final terms: EUR250m at 5.00%. Priced: 5.00% at 100. +567bp vs DBR 0.25% 02/15/29.
Did investor call at 10am UKT 01/25. Virtual meetings available through yesterday. Books closed at 10am UKT today. UOP: along with a new EUR1.45bn (down from EUR1.5bn) term loan and EUR80m cash on hand, to repay its existing EUR2.015bn term loan, existing EUR305m 2nd lien debt and existing EUR219m PIK notes. Biz: Leading private medical laboratory testing business in France and Belgium.